IRAK4 Degraders for Treating Fibrotic Diseases and Beyond

This inventive concept expands the application of IRAK4 degraders beyond MYD88-mutant B-cell lymphomas to treat fibrotic diseases, prevent scarring, and address inflammatory bowel disease and dry eye disease, leveraging the unique profile of IRAKIMiD degraders.

The original patent disclosed the use of IRAK4 degraders for treating MYD88-mutant B-cell lymphomas. However, fibrotic diseases, such as idiopathic pulmonary fibrosis, remain a significant unmet medical need. Current treatments are limited, and there is a pressing need for novel therapeutic approaches. This inventive concept addresses this limitation by applying IRAK4 degraders to fibrotic diseases, capitalizing on their ability to selectively degrade IRAK4 protein and IMiD targets.

The new claims describe methods for treating fibrotic diseases, detecting fibrotic diseases, preventing scarring, treating inflammatory bowel disease, and treating dry eye disease using IRAK4 degraders. These degraders selectively degrade IRAK4 protein and IMiD targets, thereby reducing fibrosis, inflammation, and promoting tear production. The IRAKIMiD degraders' unique profile, combining IRAK4 degradation and immunomodulatory IMiD activity, enables their application in these new disease areas. The inventive concept encompasses various IRAK4 degraders, including Compound A, and their pharmaceutically acceptable salts.

The new claims introduce a novel application of IRAK4 degraders, moving beyond the original patent's focus on MYD88-mutant B-cell lymphomas. The inventive concept's novelty lies in the recognition of IRAK4 degraders' potential in treating fibrotic diseases and related conditions, which is not obvious from the original patent.

Alternative embodiments of the inventive concept could include the use of different IRAK4 degraders, varying dosing regimens, or combination therapies with other agents. Additionally, the inventive concept could be adapted for use in other disease areas where fibrosis or inflammation play a key role.

The inventive concept has significant commercial potential in the treatment of fibrotic diseases, inflammatory bowel disease, and dry eye disease, with a combined market size projected to exceed $10 billion by 2025. The ability to address these unmet medical needs with a novel therapeutic approach positions IRAK4 degraders as a promising solution for patients and healthcare providers.